Chang Kuo-Chu, Hsu Kwan-Lih, Tseng Chuen-Den, Lin Yue-Der, Cho Yi-Li, Tseng Yung-Zu
Department of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Br J Pharmacol. 2006 Apr;147(8):944-50. doi: 10.1038/sj.bjp.0706684.
The formation of advanced glycation endproducts (AGEs) on collagen within the arterial wall may be responsible for the development of diabetic vascular injury. This study was to examine the role of aminoguanidine (AG), an inhibitor of AGEs formation, in the prevention of arterial stiffening and cardiac hypertrophy in streptozotocin (STZ) induced diabetes in rats. Diabetes was induced in animals by a single tail vein injection with 65 mg kg(-1) STZ. After confirmation of the development of hyperglycemia (2 days later), rats were treated for 8 weeks with AG (daily peritoneal injections of 50 mg kg(-1)) and compared with the age-matched untreated diabetic controls. After exposure to AG, the STZ-diabetic rats showed no alterations in cardiac output, aortic pressure profiles, total peripheral resistance, and aortic characteristic impedance. By contrast, treatment of this experimental diabetes with AG resulted in a significant increase in wave transit time (tau), from 20.4+/-0.6 to 24.7+/-0.5 ms (P<0.05) and a decrease in wave reflection factor (R(f)), from 0.78+/-0.04 to 0.53+/-0.02 (P<0.05). The decreased R(f) associated with the increased tau suggest that AG may retard the diabetes-induced augmentation in systolic load of the left ventricle coupled to its arterial system. Meanwhile, the diminished ratio of left ventricular weight to body weight suggests that prevention of the diabetes-related cardiac hypertrophy by AG may correspond to the drug-induced decline in aortic stiffening. Glycation-derived modification on aortic collagen was also found to be enhanced in rats with diabetes (+65.3%, P<0.05) and the advanced glycation process was retarded by AG treatment. We conclude that long-term administration of AG to the STZ-treated rats imparts significant protection against the diabetes-derived deterioration in vascular dynamics, at least partly through inhibition of the AGEs accumulation on collagen in the arterial wall.
动脉壁内胶原蛋白上晚期糖基化终产物(AGEs)的形成可能是糖尿病血管损伤发展的原因。本研究旨在探讨氨基胍(AG)(一种AGEs形成抑制剂)在预防链脲佐菌素(STZ)诱导的大鼠糖尿病中动脉僵硬和心脏肥大方面的作用。通过单次尾静脉注射65 mg kg⁻¹ STZ诱导动物患糖尿病。在确认高血糖症发展后(2天后),用AG对大鼠进行8周治疗(每日腹腔注射50 mg kg⁻¹),并与年龄匹配的未治疗糖尿病对照组进行比较。暴露于AG后,STZ诱导的糖尿病大鼠的心输出量、主动脉压力曲线、总外周阻力和主动脉特征阻抗均无变化。相比之下,用AG治疗这种实验性糖尿病导致波传播时间(tau)显著增加,从20.4±0.6增加到24.7±0.5 ms(P<0.05),波反射因子(R(f))降低,从0.78±0.04降低到0.53±0.02(P<0.05)。与tau增加相关的R(f)降低表明AG可能减缓糖尿病诱导的与其动脉系统相关的左心室收缩负荷增加。同时,左心室重量与体重之比的降低表明AG预防糖尿病相关的心脏肥大可能与药物诱导的主动脉僵硬减轻有关。还发现糖尿病大鼠主动脉胶原蛋白上的糖基化衍生修饰增强(+65.3%,P<0.05),而AG治疗可延缓晚期糖基化过程。我们得出结论,对STZ处理的大鼠长期给予AG可显著保护其免受糖尿病引起的血管动力学恶化,至少部分是通过抑制动脉壁胶原蛋白上AGEs的积累实现的。